The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...
Investor's Business Daily on MSN2d
Gilead Outplays Veklury Downfall To Obliterate Forecasts. Will Shares Win Back Their Breakout?Gilead obliterated fourth-quarter expectations Tuesday and issued an upbeat profit outlook for 2025. The news is likely to buoy Gilead stock.
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...
Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...
In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of $99.32, a high estimate of $125.00, and a low estimate of $80.00. This ...
Gilead Sciences, a leader in HIV drugs, faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033, making diversification crucial. The current stock price at $95+ implies 5 ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects ...
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...
Also Read: Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments The HIV drug maker reported third-quarter sales of $7.55 billion, up 7% year over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback